Galmed Pharmaceutica (GLMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 4,773 | 2,978 | 2,130 | 2,998 | 7,060 |
| Marketable Securities | 7,183 | 7,528 | 11,769 | 31,931 | 40,132 |
| Receivables | 672 | 480 | 825 | 1,125 | 812 |
| Other current assets | 3,496 | 2,253 | 0 | 0 | 3,807 |
| TOTAL | $16,124 | $13,239 | $14,724 | $36,054 | $51,811 |
| Non-Current Assets | |||||
| PPE Net | N/A | 83 | 114 | 145 | 176 |
| Investments And Advances | 2,119 | 3,265 | 1,500 | 0 | 0 |
| Other Non-Current Assets | 257 | 42 | 223 | 406 | 394 |
| TOTAL | $2,376 | $3,390 | $1,837 | $551 | $570 |
| Total Assets | $18,500 | $16,629 | $16,561 | $36,605 | $52,381 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,173 | 2,750 | 3,094 | 5,879 | 8,012 |
| TOTAL | $2,173 | $2,750 | $3,094 | $5,879 | $8,012 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 44 | 0 | 0 |
| TOTAL | $N/A | $N/A | $44 | $229 | $216 |
| Total Liabilities | $2,173 | $2,750 | $3,138 | $6,108 | $8,228 |
| Shareholders' Equity | |||||
| Common Shares | 742 | 209 | 70 | 70 | 58 |
| Retained earnings | -200,469 | -192,952 | -186,040 | -168,174 | -135,707 |
| Other shareholders' equity | -416 | -454 | -745 | -171 | 272 |
| TOTAL | $16,327 | $13,879 | $13,423 | $30,497 | $44,153 |
| Total Liabilities And Equity | $18,500 | $16,629 | $16,561 | $36,605 | $52,381 |